| Year |
Citation |
Score |
| 2023 |
Disis ML, Adams SF, Bajpai J, Butler MO, Curiel T, Dodt SA, Doherty L, Emens LA, Friedman CF, Gatti-Mays M, Geller MA, Jazaeri A, John VS, Kurnit KC, Liao JB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. Journal For Immunotherapy of Cancer. 11. PMID 37295818 DOI: 10.1136/jitc-2022-006624 |
0.336 |
|
| 2021 |
Cecil DL, Liao JB, Dang Y, Coveler AL, Kask A, Yang Y, Childs J, Higgins D, Disis ML. Immunization with a plasmid DNA vaccine encoding the N-terminus of Insulin like Growth Factor Binding Protein-2 in advanced ovarian cancer leads to high level Type I immune responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34526360 DOI: 10.1158/1078-0432.CCR-21-1579 |
0.31 |
|
| 2019 |
Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, Pennington KP, Garcia RL, Liao JB, Swisher EM. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecologic Oncology. PMID 30803719 DOI: 10.1016/J.Ygyno.2019.02.011 |
0.32 |
|
| 2019 |
Liao JB, Fisher CE, Madeleine MM. Gynecologic cancers and solid organ transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 30725527 DOI: 10.1111/Ajt.15292 |
0.402 |
|
| 2019 |
Liao JB, Gwin WR, Urban R, Hitchcock-Bernhardt K, Coveler AL, Higgins D, Childs JS, Shakalia H, Stanton SE, Tinker A, Wahl TA, Ancheta RG, McGonigle KF, Dai J, Disis ML, et al. Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results. Journal of Clinical Oncology. 37: 5519-5519. DOI: 10.1200/Jco.2019.37.15_Suppl.5519 |
0.361 |
|
| 2018 |
Gwin WR, Childs J, Higgins D, Shakalia H, Liao JB, Disis ML. Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps5613 |
0.444 |
|
| 2017 |
Johnson N, Liao JB. Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 29040190 DOI: 10.1097/Igc.0000000000001115 |
0.412 |
|
| 2017 |
Goff BA, Agnew K, Neradilek MB, Gray HJ, Liao JB, Urban RR. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecologic Oncology. PMID 28860006 DOI: 10.1016/J.Ygyno.2017.08.020 |
0.317 |
|
| 2017 |
Morse CB, Elvin JA, Gay LM, Liao JB. Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecologic Oncology Reports. 21: 78-80. PMID 28736741 DOI: 10.1016/J.Gore.2017.06.013 |
0.434 |
|
| 2017 |
Liao JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, Reichow JL, Apodaca MC, D'Amico L, Childs JS, Higgins DM, Buening BJ, Goff BA, Disis ML. Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecologic Oncology. PMID 28089377 DOI: 10.1016/J.Ygyno.2017.01.008 |
0.37 |
|
| 2017 |
Liao JB, Cecil DL, Dang Y, Baker KK, Ovenell KJ, Reichow J, Parker S, Higgins DM, Childs JS, Broussard EK, Coveler AL, Salazar LG, Goff BA, Redman MW, Disis ML. Abstract NTOC-097: VACCINATION TARGETING INSULIN–LIKE GROWTH FACTOR BINDING PROTEIN–2 (IGFBP–2) IN ADVANCED OVARIAN CANCER: SAFETY, IMMUNOGENICITY, AND SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) COMPARISON Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ntoc-097 |
0.463 |
|
| 2016 |
Martin JY, Urban RR, Liao JB, Goff BA. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. Journal of Gynecologic Oncology. e47. PMID 27329195 DOI: 10.3802/Jgo.2016.27.E47 |
0.42 |
|
| 2016 |
Liao JB. Immunotherapy for Gynecologic Cancers: State of the Science. Gynecologic Oncology. PMID 27242186 DOI: 10.1016/J.Ygyno.2016.05.029 |
0.352 |
|
| 2016 |
Liao JB, Cecil D, Dang Y, Baker KK, Ovenell KJ, Reichow J, Parker S, Higgins D, Childs J, Broussard EK, Coveler AL, Salazar LG, Goff BA, Redman MW, Disis ML. Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity. Journal of Clinical Oncology. 34: 5542-5542. DOI: 10.1200/Jco.2016.34.15_Suppl.5542 |
0.368 |
|
| 2015 |
Beck TL, Morse CB, Gray HJ, Goff BA, Urban RR, Liao JB. Route of hysterectomy and surgical outcomes from a state-wide gynecologic oncology population: is there a role for vaginal hysterectomy? American Journal of Obstetrics and Gynecology. PMID 26470825 DOI: 10.1016/J.Ajog.2015.10.006 |
0.374 |
|
| 2015 |
Liao JB, Ovenell KJ, Curtis EE, Cecil DL, Koehnlein MR, Rastetter LR, Gad EA, Disis ML. Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer. Journal For Immunotherapy of Cancer. 3: 16. PMID 25992288 DOI: 10.1186/S40425-015-0060-6 |
0.371 |
|
| 2015 |
Liao JB, Yip YY, Swisher EM, Agnew K, Hellstrom KE, Hellstrom I. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. Gynecologic Oncology. 137: 430-5. PMID 25866324 DOI: 10.1016/J.Ygyno.2015.03.044 |
0.399 |
|
| 2015 |
Liao JB, Swensen RE, Reichow J, Ovenell KJ, Childs J, Higgins D, Buening B, Goff BA, Morishima C, Disis ML. Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses. Journal of Clinical Oncology. 33: 5580-5580. DOI: 10.1200/Jco.2015.33.15_Suppl.5580 |
0.415 |
|
| 2014 |
Liao JB, Reichow JL, Higgins DM, Childs JS, Salazar LG, Disis ML. Persistent immunity after therapeutic vaccination targeting HER2/neu correlated with post-vaccination magnitude of interferon gamma Elispot responses Journal For Immunotherapy of Cancer. 2: 53. DOI: 10.1186/2051-1426-2-S3-P53 |
0.349 |
|
| 2014 |
Dao MD, Zsiros E, Urban RR, Gray HJ, Tamimi HK, Goff BA, Tanyi JL, Liao JB. Prognostic factors for overall survival in recurrent ovarian, fallopian tube, and peritoneal cancer patients treated with bevacizumab: A multisite study Gynecologic Oncology. 133: 99-100. DOI: 10.1016/J.Ygyno.2014.03.264 |
0.391 |
|
| 2014 |
Liao JB, Ovenell KJ, Wu M, Agnew KJ, Harrell MI, Swisher EM, Goff BA, Disis ML. Serum antibodies recognizing BRCA1 at time of diagnosis and primary platinum resistance in ovarian cancer Gynecologic Oncology. 133: 97. DOI: 10.1016/J.Ygyno.2014.03.258 |
0.355 |
|
| 2014 |
Dao MD, Agnew KJ, Swisher EM, Goff BA, Disis ML, Liao JB. Serum antibodies recognizing hypoxia-inducible factor 1-alpha and platinum sensitivity in ovarian cancer Gynecologic Oncology. 133: 71-72. DOI: 10.1016/J.Ygyno.2014.03.193 |
0.33 |
|
| 2014 |
Liao JB, Cecil DL, Reichow J, Parker S, Higgins D, Childs J, Broussard E, Coveler A, Salazar L, Disis ML. A phase I trial of a DNA plasmid-based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: Preliminary safety and immunogenicity Gynecologic Oncology. 133: 30. DOI: 10.1016/J.Ygyno.2014.03.094 |
0.363 |
|
| 2013 |
Liao JB, Disis ML. Therapeutic vaccines for ovarian cancer. Gynecologic Oncology. 130: 667-73. PMID 23800697 DOI: 10.1016/J.Ygyno.2013.06.023 |
0.395 |
|
| 2013 |
Dao MD, Alwan LM, Gray HJ, Tamimi HK, Goff BA, Liao JB. Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology. 130: 295-9. PMID 23632207 DOI: 10.1016/J.Ygyno.2013.04.055 |
0.382 |
|
| 2012 |
Liao J, Poussin M, Hasegawa K, Song D, Powell D, Coukos G. Pegylated liposomal doxorubicin augments the efficacy of engineered human T cells expressing a p53-specific T cell receptor against ovarian cancer Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.106 |
0.33 |
|
| 2011 |
Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, Chu CS. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecologic Oncology. 120: 464-9. PMID 21168199 DOI: 10.1016/J.Ygyno.2010.11.009 |
0.309 |
|
| 2011 |
Liao JB, Jean S, Wilkinson-Ryan I, Ford AE, Tanyi JL, Hagemann AR, Lin LL, McGrath CM, Rubin SC. Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity. Gynecologic Oncology. 120: 108-12. PMID 20937524 DOI: 10.1016/J.Ygyno.2010.09.005 |
0.301 |
|
| 2010 |
Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ, Coukos G. The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecologic Oncology. 116: 222-33. PMID 19959212 DOI: 10.1016/J.Ygyno.2009.11.001 |
0.425 |
|
| 2008 |
Liao JB, Publicover J, Rose JK, DiMaio D. Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein. Clinical and Vaccine Immunology : Cvi. 15: 817-24. PMID 18337377 DOI: 10.1128/Cvi.00343-07 |
0.551 |
|
| 2006 |
DiMaio D, Liao JB. Human papillomaviruses and cervical cancer. Advances in Virus Research. 66: 125-59. PMID 16877060 DOI: 10.1016/S0065-3527(06)66003-X |
0.56 |
|
| 2001 |
Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology. 82: 532-7. PMID 11520151 DOI: 10.1006/Gyno.2001.6328 |
0.351 |
|
| Show low-probability matches. |